ArticleBMC infectious diseases2026
Snapshot based on whole-genome sequencing revealing the species and antimicrobial susceptibility profiles of Mycobacterium tuberculosis complex recovered at a major tertiary care center in Lebanon.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTuberculosis remains a pressing public health issue in Lebanon. The aim of this study was whole-genome-based determination of species and sub-species and antibiotic susceptibility profiles of Mycobacterium tuberculosis complex (MTBC) isolates recovered from a major tertiary care center in Lebanon.
methodsA total of 48 clinical MTBC isolates were identified and characterized through whole genome sequence using Illumina MiSeq.
resultsGenomic analysis revealed that 39/48 (81.25%) of the clinical isolates were M. tuberculosis and 9/48 (18.75%) were Mycobacterium bovis. M. tuberculosis was distributed over four lineages, Indo-Oceanic L1 (n = 3/39; 7.6%), East-Asian L2 (n = 1/39; 2.5%), East-African Indian L3 (n = 5/39; 12.8%) and Euro-American L4 (n = 30/39; 76.9%). Sub-lineage L4.8 (Euro-American, mainly T), comprising 8/39 of the isolates (20.5%) was predominant, followed by sub-lineages L3 (East-African Indian, n = 5/39 isolates; 12.8%), L4.2.2.2 (Euro-American (Ural), n = 4/39 isolates; 10.2%) and L4.6.5 (Euro American, n = 4/39 isolates; 10.2%). The nine M. bovis isolates were clustered into two separate clades, designated as unknown 2 (n = 2/9, 22.2%) and unknown 3 (n = 7/9, 77.8%). Further genome-wide single nucleotide polymorphism (SNP) analyses identified two possible transmission clusters, each comprising isolates differing by < 12 SNPs, consistent with recent transmission events. In silico antimycobacterial susceptibility profiling against 13 drugs showed uniform susceptibility among 24/39 (61.53%) M. tuberculosis isolates while the M. bovis isolates were susceptible to all the antimycobacterial drugs except pyrazinamide.
conclusionsThis study characterized the molecular features, clustering patterns, and resistance profiles of human MTBC isolates, and identified the lineages and sub-lineages of M. tuberculosis along with their prevalence. Unexpectedly, our findings also revealed the presence of M. bovis, which is often misidentified due to the limited availability of facilities for molecular typing and characterization of MTBC isolates. This identification helps improve the detection of the causative agents of tuberculosis and assess the zoonotic contribution. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.